hrcak mascot   Srce   HID

Izvorni znanstveni članak

REIMBURSEMENT OF GENERICS IN CROATIA: SHOULD MORE HAVE BEEN DONE

MARIJO VUKUŠIĆ

Puni tekst: hrvatski, pdf (310 KB) str. 134-143 preuzimanja: 634* citiraj
APA 6th Edition
VUKUŠIĆ, M. (2010). NADOKNADA TROŠKA LIJEKA U HRVATSKOJ: JE LI SE MOGLO UČINITI VIŠE?. Liječnički vjesnik, 132 (5-6), 134-143. Preuzeto s https://hrcak.srce.hr/63574
MLA 8th Edition
VUKUŠIĆ, MARIJO. "NADOKNADA TROŠKA LIJEKA U HRVATSKOJ: JE LI SE MOGLO UČINITI VIŠE?." Liječnički vjesnik, vol. 132, br. 5-6, 2010, str. 134-143. https://hrcak.srce.hr/63574. Citirano 21.01.2020.
Chicago 17th Edition
VUKUŠIĆ, MARIJO. "NADOKNADA TROŠKA LIJEKA U HRVATSKOJ: JE LI SE MOGLO UČINITI VIŠE?." Liječnički vjesnik 132, br. 5-6 (2010): 134-143. https://hrcak.srce.hr/63574
Harvard
VUKUŠIĆ, M. (2010). 'NADOKNADA TROŠKA LIJEKA U HRVATSKOJ: JE LI SE MOGLO UČINITI VIŠE?', Liječnički vjesnik, 132(5-6), str. 134-143. Preuzeto s: https://hrcak.srce.hr/63574 (Datum pristupa: 21.01.2020.)
Vancouver
VUKUŠIĆ M. NADOKNADA TROŠKA LIJEKA U HRVATSKOJ: JE LI SE MOGLO UČINITI VIŠE?. Liječnički vjesnik [Internet]. 2010 [pristupljeno 21.01.2020.];132(5-6):134-143. Dostupno na: https://hrcak.srce.hr/63574
IEEE
M. VUKUŠIĆ, "NADOKNADA TROŠKA LIJEKA U HRVATSKOJ: JE LI SE MOGLO UČINITI VIŠE?", Liječnički vjesnik, vol.132, br. 5-6, str. 134-143, 2010. [Online]. Dostupno na: https://hrcak.srce.hr/63574. [Citirano: 21.01.2020.]

Sažetak
Background: while numerous ordinances on drug pricing and reimbursement have been enacted, trying to suppress the drug expenditure in Croatia, it seemed there were inconsistencies in pricing procedures of some of the drugs. Objectives: to show whether or not the pricing system given has had the desired result, we review pricing and reimbursement systems of generics in some of the EU countries and give suggestions for even more effective pricing and reimbursement system in Croatia. Data and Method: IMS Sales Data for the years 2004 to 2007 were used to show the differences between desired and real price levels of generics within the control group. Results: detailed analysis of the observed group of drugs showed that inappropriately priced drugs accounted for 100% in the year 2004 and fell to 60% of total expenditure within the observed group in the year 2007. The reference pricing system should be enacted, free price setting and financial incentives for physicians and pharmacists, as well as private insurance packages for non-reimbursed service or drugs or co-payments.

Ključne riječi
Drug costs – legislation and jurisprudence; Drugs, generic – economics; Drug utilization – economics; Legislation, drug; Pharmaceutical services – legislation and jurisprudence, economics; Insurance, health – legislation and jurisprudence; Croatia

Hrčak ID: 63574

URI
https://hrcak.srce.hr/63574

[hrvatski]

Posjeta: 972 *